Directing stem cells down the pancreatic line
Tuesday, 17 March, 2009
High content screening has allowed US researchers to identify a molecule that can direct human embryonic stem cells down the pancreatic path, with the hope of eventually creating insulin-producing beta cells.
The researchers, led by Professor Doug Melton of Harvard University, used a high-content screen to identify (–)-indolactam V (ILV), which seems to increase the number of cells derived from hESCs that express Pdx1, a transcription factor needed for pancreatic development.
When combined with growth factors, ILV can nudge hESCs along such that more than 45 per cent become pancreatic progenitor cells.
These cells are thought to be the common progenitor for the entire pancreas, forming duct, exocrine and endocrine tissues, the researchers write.
They say this method would be less expensive and more easily controllable than using co-culture with other cell types.
The study is published online in advance in Nature Chemical Biology Nature Chemical Biology.
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
AI-driven manufacturing: lessons from the life sciences industry
The use of artificial intelligence for batch monitoring and digital twin development is...
Does paracetamol use in pregnancy cause autism? Experts respond
White House Press Secretary Karoline Leavitt says there is "mounting evidence finding a...